GSK to buy Nuvalent for $10.6B, snagging two experimental lung-cancer drugs
TL;DR
GSK plans a $10.6 billion acquisition of Nuvalent to gain two experimental lung-cancer medicines (Zidesamtinib and Neladalkib) currently under FDA review, bolstering its oncology pipeline amid a major biotech deal.
- GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B Endpoints News
- Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion CNBC
- GSK to Buy Nuvalent for $10.6 Billion in Oncology Push WSJ
- GSK enters agreement to acquire Nuvalent, Inc. GSK
- GSK to buy US cancer biotech Nuvalent for $10.6bn Financial Times
Want the full story? Read the original reporting
Read on Endpoints News